Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua. [PDF]
J Thromb Haemost, 2021 Limited information exists regarding the factor IX (FIX) coagulant activity (FIX:C) measured by different assays following FIX‐Padua gene therapy.
Robinson MM +9 more
europepmc +2 more sources
Successful immunosuppressive drug‐free immune tolerance induction in hemophilia B with inhibitor and anaphylaxis to factor IX: A case report [PDF]
Clinical Case ReportsKey Clinical Message Recommendations advise factor IX desensitization before immune tolerance induction in severe hemophilia B, supported by immunosuppression.
Ángeles Palomo Bravo +4 more
doaj +2 more sources
Beware of Reversal of an Anticoagulated Patient with Factor IX in the Emergency Department: Case Report of a Medical-Legal Misadventure [PDF]
Clinical Practice and Cases in Emergency Medicine, 2020 In this article we present a case of a patient who received reversal of anticoagulation therapy with factor IX in violation of hospital guidelines. As a direct result, myocardial infarction and ischemic stroke occurred, leaving the patient neurologically
Steven Gannon +3 more
doaj +2 more sources
Journal of Tissue Engineering, 2012 Cell microencapsulation holds significant promise as a strategy for cellular therapies; however, inadequate survival and functionality of the enclosed cells limit its application in hemophilia treatment.
Bahareh Sayyar +6 more
doaj +2 more sources
A Post-Authorization Safety Surveillance Study to Report Clinical Experience with Purified Factor IX Concentrate in Pediatric Patients with Hemophilia B [PDF]
Journal of Blood MedicineZoran Igrutinović,1,2 Hélène Louise Hooimeijer,3 Karim Kentouche,4 Jaco Botha,5 Peter L Turecek,6 Marta Kokot-Kierepa,5 Hanna T Gazda7 1Clinic of Pediatrics, Department of Hemato-Oncology, University Clinical Center of Kragujevac, Kragujevac ...
Igrutinović Z +6 more
doaj +2 more sources
Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand. [PDF]
Res Pract Thromb Haemost, 2023 Álvarez-Román MT +7 more
europepmc +3 more sources
Peri-operative Management and the Role of Minimally Invasive Spine Surgery in a Case of Hemophilia B [PDF]
Journal of Minimally Invasive Spine Surgery and Technique, 2022 Hemophilia A and B are rare X-chromosome-linked recessive bleeding disorders caused by mutations in the genes causing abnormalities of blood clotting factors VIII and IX, respectively.
VNR Praveen Goparaju +3 more
doaj +1 more source
Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments. [PDF]
Semin Thromb Hemost, 2023 Bowyer AE, Gosselin RC.
europepmc +3 more sources
Current Medical Research and Opinion, 2022 Objective Congenital hemophilia B is a rare bleeding disorder caused by defects in the gene encoding factor IX (FIX) leading to coagulation deficiency. Recurrent bleeds may cause chronic pain, disability, and reduced quality of life.
Jinesh Shah +4 more
semanticscholar +1 more source